Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
about
Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticityHIV-1 neutralizing antibodies: understanding nature's pathwaysDifferences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder VirusHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesInduction of a Tier-1-like Phenotype in Diverse Tier-2 Isolates by Agents that Guide HIV-1 Env to Perturbation-sensitive, Non-native States.Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse modelA V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1.A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.Characterization of primary isolate-like variants of simian-human immunodeficiency virusImproved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropismVirus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolatesIncreased neutralization sensitivity of CD4-independent human immunodeficiency virus variantsDifferential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaquesImpact of natural polymorphism within the gp41 cytoplasmic tail of human immunodeficiency virus type 1 on the intracellular distribution of envelope glycoproteins and viral assembly.Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies.Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicityMechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibodyCD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env SequencesA novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assaysNeutralizing antibodies to HIV-1 induced by immunization.
P2860
Q24806405-CE89DCC7-9E95-4420-AC8D-6D1535279F64Q27000480-4D7B8C25-F973-47CE-9CEE-B0707437AB04Q28551914-334B6508-ED14-4787-B419-26AEE14EC401Q28602877-B7415295-043E-4E25-9150-E3608927E48FQ29619015-A3C324AF-B054-48FD-AA5F-837724E53160Q30401836-66005DD3-ABE7-49A5-B17E-94D4481E0782Q30431941-D02B256C-BA59-4DC0-9D56-0C04F5594319Q33647300-C944FC11-5E96-42CB-BFA0-B0BE1382D233Q33676640-2DF0467D-19A3-4B89-8885-0C3D027023E8Q33725702-B78C79B9-88EE-4DDE-AEEE-D613824BD01DQ33783516-96728AF1-B1C0-4D5F-8125-8907DFDD76F8Q33784679-7459DF41-81BD-4F8E-86AE-D0DB1C11674FQ33788810-BDEE72A4-B187-46ED-8B8F-698E7E13C4A9Q33815502-529C5F88-F7E3-44BA-A2ED-E0AC124952A6Q33822395-39D48F23-E958-4965-945E-5A1CF1A3BAFEQ33825229-B5FE8323-6AA6-4E32-A12E-F836D2C1942DQ33836042-AAF40A02-3DA5-47C2-87AB-1B9B97ADFAA5Q33842152-F5A638D2-5842-4E9E-9A42-6988B4B656A8Q33842455-59545BFC-8DF7-4FBC-8CB4-26A1F8B89D1FQ33843345-32684D91-4804-4194-9545-0DE7B66F7263Q33844079-19ECB4A6-08CC-447F-ACBC-B47EB641D0D0Q33850415-80746404-6646-4263-8D7C-61F1BBA8348AQ33851094-5FE67412-D152-4CE1-9ECE-89D301E39445Q33951963-2ACF39FE-F917-4D0D-8223-28BE9641E580Q34069214-CD586AA4-BB9D-45D1-994B-D38374F371B1Q34154514-221FD5C7-29F2-4269-BE18-AEF704F90C62Q35634348-74FF4318-C261-44FC-8113-D288E1B9B836Q35785244-D97B204D-798A-484C-B7A5-FE2902C4F82CQ35839973-CC51BE0A-933F-4B62-9785-302001C3EC68Q35848446-9900928C-8237-40D3-B395-F12FD44336ABQ35849408-D210EFF0-17EF-455D-B5B6-0D6DED2D7F20Q35854001-1EAC5DC1-F00B-42CD-824D-C6BEAEE10B13Q35857631-995E3290-FB29-462A-8160-03229AA09C9CQ35866030-3A7E5B8B-DC67-4F92-8F2E-88B99F206ACFQ35876191-06D560DC-34A2-4B7F-B769-6275C8A4CE95Q35887822-8D8CB96B-0A39-49BF-8AA0-EA049A43EFC7Q35896178-D8D3DFD1-0E8E-4BB2-8A7F-44225EDE89EAQ35915764-A19AAB18-3D60-481B-BE5F-5C8FFA5FBFB2Q36363866-47EDD3AE-C0EB-4E8C-9311-340DE82203A7Q36603515-63F55ED6-B6D3-4D43-A2F6-46B9FA62C0C5
P2860
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Adaptation to persistent growt ...... neutralization by vaccine sera
@ast
Adaptation to persistent growt ...... neutralization by vaccine sera
@en
type
label
Adaptation to persistent growt ...... neutralization by vaccine sera
@ast
Adaptation to persistent growt ...... neutralization by vaccine sera
@en
prefLabel
Adaptation to persistent growt ...... neutralization by vaccine sera
@ast
Adaptation to persistent growt ...... neutralization by vaccine sera
@en
P2093
P2860
P1433
P1476
Adaptation to persistent growt ...... neutralization by vaccine sera
@en
P2093
P2860
P407
P577
1995-01-01T00:00:00Z